Treatment strategies for metastatic castration-sensitive prostate cancer: From “all-comers” to “personalized” approach

Medicine and Dentistry

• Therapeutic Procedure 100%
• Patient 83%
• Prostate Cancer 83%
• Androgen Deprivation Therapy 83%
• Combination Therapy 66%
• Clinical Trial 50%
• Overall Survival 50%
• Enzalutamide 33%
• Docetaxel 33%
• Radiation 33%
• Neoplasm 16%
• Toxicity 16%
• Diagnosis 16%
• Biological Product 16%
• Biological Marker 16%
• Man 16%
• Survival 16%
• Long Term Survival 16%
• Androgen Receptor 16%
• Clinical Feature 16%
• Evolution 16%
• Prostate 16%
• Apalutamide 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 83%
• Combination Therapy 66%
• Overall Survival 50%
• Cancer Risk 33%
• Enzalutamide 33%
• Docetaxel 33%
• Abiraterone Acetate 33%
• Toxicity 16%
• Biological Marker 16%
• Neoplasm 16%
• Clinical Feature 16%
• Biological Product 16%
• Survival 16%
• Androgen Receptor 16%
• Long Term Survival 16%
• Apalutamide 16%

Biochemistry, Genetics and Molecular Biology

• Volume 50%
• Overall Survival 50%
• Enzalutamide 33%
• Radiation 16%
• Evolution 16%
• Survival 16%
• Tumor Volume 16%
• Androgen Receptor 16%
• Long Term Survival 16%